5-hydroxytryptophan has been researched along with Paraparesis in 1 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Paraparesis: Mild to moderate loss of bilateral lower extremity motor function, which may be a manifestation of SPINAL CORD DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; MUSCULAR DISEASES; INTRACRANIAL HYPERTENSION; parasagittal brain lesions; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We describe two sisters with hemiplegic migraine, low CSF and platelet serotonin levels, and progressive spastic paraparesis associated with profound spinal cord atrophy whose lower extremity strength and ambulation responded to a precursor replacement strategy (5-hydroxytryptophan and carbidopa administration), an approach that may have broader applicability in myelopathies of diverse etiology where descending serotonergic projections are compromised." | 7.85 | Improved strength on 5-hydroxytryptophan and carbidopa in spinal cord atrophy. ( Carleton, B; Horvath, GA; Meisner, L; Selby, K; Stowe, R, 2017) |
| " We describe two sisters with hemiplegic migraine, low CSF and platelet serotonin levels, and progressive spastic paraparesis associated with profound spinal cord atrophy whose lower extremity strength and ambulation responded to a precursor replacement strategy (5-hydroxytryptophan and carbidopa administration), an approach that may have broader applicability in myelopathies of diverse etiology where descending serotonergic projections are compromised." | 3.85 | Improved strength on 5-hydroxytryptophan and carbidopa in spinal cord atrophy. ( Carleton, B; Horvath, GA; Meisner, L; Selby, K; Stowe, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horvath, GA | 1 |
| Meisner, L | 1 |
| Selby, K | 1 |
| Stowe, R | 1 |
| Carleton, B | 1 |
1 other study available for 5-hydroxytryptophan and Paraparesis
| Article | Year |
|---|---|
Improved strength on 5-hydroxytryptophan and carbidopa in spinal cord atrophy.
Topics: 5-Hydroxytryptophan; Adult; Atrophy; Carbidopa; Central Nervous System Agents; Fatal Outcome; Female | 2017 |